<DOC>
	<DOC>NCT02706678</DOC>
	<brief_summary>The objective of this study is to evaluate the effects of tacrolimus sustained-release capsules replacing cyclosporin on kidney function of renal transplant recipients.</brief_summary>
	<brief_title>Efficacy and Safety Study of the Switch From Cyclosporin to Tacrolimus in Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>1865 years of age, male or female 15 years after kidney transplantation The patient has been accepting cyclosporinbased immunosuppressive therapy for ≥6 months, and the therapeutic regimen has kept stable for at least 4 weeks before inclusion The dose of cyclosporin has kept stable for at least 4 weeks before inclusion At least one of the cyclosporinrelated adverse reactions is present or the answer to the 5th question in the questionnaire is "Yes" at the time of inclusion: gingival hyperplasia and treatment requested by the patient polytrichia and interventional therapy requested by the patient posttransplantation hypertension posttransplantation hyperlipemia (total cholesterol&gt;5.7 mmol/L (220 mg/dl)) Serum creatinine&lt;200 μmol/l ( 2.3 mg/dl) A promise is made to take contraceptive measures during the study (women at childbearing ages). Patients having accepted transplantation of other organs apart from kidney transplantation Patients with 24hour urine protein&gt;2 g Patients with SGPT/ALT, SGOT/AST or total bilirubin continually increasing to more than twice the normal value(s) Patients with refractory infectious foci Patients with serious diarrhea or vomiting, active upper gastrointestinal ulcers or malabsorption Patients with serious heart or lung diseases or history of sugar tolerance abnormality or malignant tumors Patients allergic to tacrolimus or other basic medications Pregnant or lactating women Patients having participated in other clinical trials within the previous month Other patients who are considered by doctors unsuitable for the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>FK506</keyword>
	<keyword>Renal transplant recipients</keyword>
	<keyword>cyclosporin</keyword>
</DOC>